Dashboard
Manage Tickers

IPHA


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

innate-pharma-reports-564m-cash-and-23m-nine-month-revenue-as-lacutamab-advances-toward-tellomak-3-phase-3-initiation-in-2026
Innate Pharma Reports €56.4M Cash And €2.3...
11/13/2025 06:18:21

Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 202...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
11/11/2025 12:07:21

why-rocket-lab-shares-are-trading-higher-by-over-9-here-are-20-stocks-moving-premarket
Why Rocket Lab Shares Are Trading Higher B...
11/11/2025 10:55:19

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
11/10/2025 17:07:01

innate-pharma-gains-fda-clearance-to-launch-tellomak-3-phase-3-trial-of-lacutamab-in-szary-syndrome-and-mycosis-fungoides
Innate Pharma Gains FDA Clearance To Launc...
11/10/2025 06:32:52

The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome ...

this-edwards-lifesciences-analyst-turns-bullish-here-are-top-4-upgrades-for-wednesday
This Edwards Lifesciences Analyst Turns Bu...
10/29/2025 11:43:31

hc-wainwright--co-upgrades-innate-pharma-to-buy-announces-5-price-target
HC Wainwright & Co. Upgrades Innate Pharma...
10/29/2025 11:10:49

HC Wainwright & Co. analyst Swayampakula Ramakanth upgrades Innate Pharma (NASDAQ:IPHA) from Neutral to Buy and announce...

btig-reiterates-buy-on-innate-pharma-maintains-8-price-target
BTIG Reiterates Buy on Innate Pharma, Main...
10/29/2025 09:34:50

BTIG analyst Justin Zelin reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $8 price target.

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 12:09:03

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 12:09:34

this-progressive-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-thursday
This Progressive Analyst Is No Longer Bull...
09/18/2025 14:00:34

alphabet-to-rally-more-than-14-here-are-10-top-analyst-forecasts-for-thursday
Alphabet To Rally More Than 14%? Here Are ...
09/18/2025 12:16:40

leerink-partners-downgrades-innate-pharma-to-market-perform-lowers-price-target-to-2
Leerink Partners Downgrades Innate Pharma ...
09/18/2025 11:11:32

Leerink Partners analyst Daina Graybosch downgrades Innate Pharma (NASDAQ:IPHA) from Outperform to Market Perform and lowers...

hc-wainwright--co-downgrades-innate-pharma-to-neutral
HC Wainwright & Co. Downgrades Innate Phar...
09/18/2025 10:23:09

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Innate Pharma (NASDAQ:IPHA) from Buy to Neutral.

Core News & Articles
Earnings Scheduled For September 17, 2025
09/17/2025 08:32:11

innate-pharma-h1-eps-028-up-from-034-yoy-sales-551m-down-from-1335m-yoy
Innate Pharma H1 EPS $(0.28) Up From $(0.3...
09/17/2025 05:50:37

Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.28) per share. This is a 16.76 percent increase over losses of $(0...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
07/28/2025 12:08:27

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
07/18/2025 12:07:40

innate-pharma-presents-iph6501-preclinical-data-at-eha-2025-highlighting-potential-in-relapsed-refractory-and-untreated-cd20-b-nhl
Innate Pharma Presents IPH6501 Preclinical...
06/13/2025 06:28:24

Preclinical data from IPH6501, Innate's proprietary ANKET® targeting CD20, demonstrating potent antitumor activity in vitro...

innate-pharma-highlights-long-term-clinical-benefit-of-lacutamab-in-szary-syndrome-and-mycosis-fungoides-at-asco-2025
Innate Pharma Highlights Long-Term Clinica...
05/23/2025 05:41:56

Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS) and mycosis fungoides (MF) will be presented a...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION